JPS6352923B2 - - Google Patents
Info
- Publication number
- JPS6352923B2 JPS6352923B2 JP56074133A JP7413381A JPS6352923B2 JP S6352923 B2 JPS6352923 B2 JP S6352923B2 JP 56074133 A JP56074133 A JP 56074133A JP 7413381 A JP7413381 A JP 7413381A JP S6352923 B2 JPS6352923 B2 JP S6352923B2
- Authority
- JP
- Japan
- Prior art keywords
- membrane
- methacrylate
- cellulose acetate
- stock solution
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000012528 membrane Substances 0.000 claims description 41
- 229920000642 polymer Polymers 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 229920002301 cellulose acetate Polymers 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 11
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims description 4
- -1 methacrylate ester Chemical class 0.000 claims description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 3
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims description 3
- 230000021736 acetylation Effects 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 claims description 2
- NHARPDSAXCBDDR-UHFFFAOYSA-N propyl 2-methylprop-2-enoate Chemical compound CCCOC(=O)C(C)=C NHARPDSAXCBDDR-UHFFFAOYSA-N 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 239000011550 stock solution Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 238000006116 polymerization reaction Methods 0.000 description 9
- 230000015271 coagulation Effects 0.000 description 8
- 238000005345 coagulation Methods 0.000 description 8
- 239000012510 hollow fiber Substances 0.000 description 7
- 238000009987 spinning Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001112 coagulating effect Effects 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- YRLUREUNFIRYNP-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.C=CN1CCCC1=O YRLUREUNFIRYNP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 229920000205 poly(isobutyl methacrylate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Landscapes
- Artificial Filaments (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Reinforced Plastic Materials (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Description
本発明は酢酸セルロースと(メタ)アクリル酸
エステル系重合体(共重合体)とのブレンドから
なる多孔性膜に関する。
多孔性膜については既に種々のものが開発され
てきている。医療用途にも多孔性膜が使用され、
人工腎臓、人工肝臓及び血漿交換法などでは分子
量が数千乃至数百万程度の物質に対し透過性のあ
る多孔性膜が要求されている。またこのような医
療用途は血液と多孔性膜とが接触することから血
液凝固の起り難い生体適合性のある材料が多光性
膜として要求されている。
しかしながら、中高分子量をもつ物質の透過性
能と生体適合性とを兼備した多孔性膜は実在しな
いのではないかと考えられてきた。
本発明者は、2成分の相違する重合体を同一溶
媒に溶解してブレンドを得、このブレンド物の溶
液を凝固性浴内で膜状に形成することによつてブ
レンドからなる多孔性膜を得る研究を行つている
過程で、物質透過性と生体適合性のある組成を見
い出して本発明に到達したものである。
従来の研究によれば、2種の同一溶媒に可溶な
重合体の場合に於いても相分離が起りやすく高分
子材料として特殊の場合を除いて機械的性質が劣
り実用性がないか、または機能面からその用途が
限られていたのが実状である。
しかるに、多孔性膜を湿式法で製造する場合に
は良溶媒に相分離を促進する助剤又は非溶媒を加
えて製膜原液を作つている点から考えると2種の
重合体混合による相分離性は程度によつては有利
となることも考えられる。また、血液と高分子材
料との相互作用に関する最近の研究成果として、
スチレンとヒドロキシエチルメタアクリレート重
合体との混合物からなるミクロ不均一構造体は血
液凝固(血栓)が起き難いことが発見されてい
る。もつとも、この混合体組成では機械的強度が
小さく、実用性のある多孔性膜に形成できない。
本発明は、膜材料の機械的強度、物質透過性及
び生体適合性を備えた多孔性膜を提供することを
目的とする。
本発明の構成は、酢酸セルロースとメタクリル
酸エステルの重合体又は共重合体とのブレンドか
らなる多孔性膜である。
以下、本発明を説明する。
本発明に供する酢酸セルロースとしては、酢化
度50%〜62%のものが適用できる。また酢酸セル
ロースの重合度は80〜400程度のものが使用でき
る。
メタクリル酸エステル重合体としては、メタク
リル酸メチル、メタクリル酸エチル、メタクリル
酸プロピル(n又はイソ)、メタクリル酸ブチル
(n、イソまたはtert)の各々の重合体及びこれ
らの共重合体が使用可能である。共重合体成分と
してはアクリル酸メチル、アクリル酸エチル、ア
クリル酸ブチルなどが使用されるが別にこれに限
定されない。
錯酸セルロースとメタクリル酸エステル重合体
又はその共重合体との組成は、錯酸セルロースが
50%〜90%が機械的強度の点で好ましい条件とい
えるが、製膜方法によつては、これに限定される
ものではない。
溶剤は、酢酸セルロース及びメタクリル酸エス
テル(共)重合体の両者が溶解するものであれば
如何なるものでもよい。一般的に使えるものを例
示すると、メチレンクロライド、アセトン、メチ
ルエチルケトン、酢酸エチル、N−メチルピロリ
ドン、ジメチルスルホキシドなどである。
多孔性膜の孔径を0.1μ以上に大きくしたい場合
には、非溶媒を混用して、非溶媒を空孔形成剤と
して使用する。非溶剤は両者の重合体を溶解しな
い有機液体であればよい。例えば、ヘキサン、シ
クロヘキサン、シクロヘキサノール、メタノー
ル、エタノール、プロパノール、ブタノールなど
が挙げられる。
相分離の速度をあげて、膜の孔径を大きくする
には、無機塩を加えることが有利である。無機塩
としては、アンモニウム塩、カルシウム塩、マグ
ネシウム塩などが使用出来る。
この様に、醋酸セルロース、メタクリル酸エス
テル重合体又はその共重合体、溶剤、非溶剤及び
無機塩がほぼ完全に溶解していることが製膜用原
液の必要条件である。製膜する前には過工程を
経て異物を除去する必要がある。
重合体濃度は、製膜しやすい粘度を考慮して技
術的な判断で決めるが、5〜20%の範囲が好まし
い。非溶剤は10〜50%、塩類は5〜10%の範囲
で、残りが溶剤の濃度である。塩類を使用する場
合には、20%以内の濃度でメタノールを使用する
のが有利である。
これらの溶解方法は、技術的に難しい点はない
が、先ず両重合体を溶剤に完全に溶解する。場合
によつては常温から50℃まで昇温すれば5時間で
溶解する。
次に残りの非溶剤、塩類メタノール溶液を加
え、更に5時間撹拌すれば透明な原液が得られ
る。この原液を多孔性膜に製膜する方法は、一般
の湿式製膜と何ら異なることはないが、平膜又は
中空糸膜など多孔性膜の形態によつて若干異な
る。
先ず、平膜について説明すると、凝固浴として
水または水/メタノール混合液に前述の原液を流
延すればよい。温度は溶剤の蒸発しにくい20℃以
下で行うような配慮が好ましい。
最近、多孔性膜を細い中空糸膜として使用する
方法が普及しているので、この方法について説明
する。
重合体原液を環状紡糸孔から吐出し、紡糸孔よ
り下方に数cm〜10数cmの凝固液面に落下させる。
この場合、中空糸膜の内側にも凝固液を流すこと
が平膜と異なる点である。凝固浴としては、水、
メタノールなどが使用可能である。温度は、原液
及び凝固浴共に30℃以下にするのが好ましい。ま
た紡糸孔下には、溶剤蒸発を抑制するための紡糸
筒を設けることが有利である。
以上、述べた如く、多孔性膜の製法は従来法と
特に差はないが、醋酸セルロースとメタクル酸エ
ステル重合体又は共重合体とのブレンドすること
により物質透過性及び生体適合性のよい多孔性膜
が得られる利点がある。
以下、実施例を挙げて説明する。
実施例 1
原液は、醋化度55%重合度180のセルロースア
セテートと重合度800のポリメチルメタクリレー
トを夫々120g及び30gをアセトン350gに加え、
50℃において5時間要して溶解した。シクロヘキ
サノール300gを加え、更に塩化アンモニウム50
g及びメタノール150gを加え撹拌した。この原
液を20℃に保持し、ガラス板上に流延し、これを
水:メタノール(1:1)の凝固浴にて固化させ
た。
この膜について、牛血清グロブリンの0.2%水
溶液の透過性を測定した。比較の膜として、同様
の条件で得た醋酸セルロースのみのものを用い
た。
The present invention relates to a porous membrane made of a blend of cellulose acetate and a (meth)acrylic acid ester polymer (copolymer). Various porous membranes have already been developed. Porous membranes are also used in medical applications.
Artificial kidneys, artificial livers, plasma exchange methods, and the like require porous membranes that are permeable to substances with molecular weights of several thousand to several million. Furthermore, in such medical applications, since blood and the porous membrane come into contact, a biocompatible material that is unlikely to cause blood coagulation is required as the multiphotonic membrane. However, it has been thought that there is no porous membrane that has both permeability for medium-high molecular weight substances and biocompatibility. The present inventor obtained a blend by dissolving two different polymers in the same solvent, and formed a porous membrane made of the blend by forming a solution of this blend into a membrane in a coagulating bath. In the course of conducting research to obtain the desired results, the present invention was achieved by discovering a composition that is permeable to substances and biocompatible. According to previous research, even in the case of two types of polymers that are soluble in the same solvent, phase separation is likely to occur, resulting in poor mechanical properties and impractical use except in special cases as a polymer material. The reality is that its use has been limited due to its functionality. However, when manufacturing porous membranes using a wet method, the membrane forming stock solution is prepared by adding an auxiliary agent or non-solvent that promotes phase separation to a good solvent. Depending on the degree, gender may be advantageous. In addition, recent research results regarding the interaction between blood and polymeric materials include:
It has been discovered that microheterogeneous structures made of mixtures of styrene and hydroxyethyl methacrylate polymers are less susceptible to blood coagulation (thrombus). However, this mixture composition has low mechanical strength and cannot be formed into a practical porous membrane. An object of the present invention is to provide a porous membrane having the mechanical strength, substance permeability, and biocompatibility of the membrane material. The composition of the present invention is a porous membrane consisting of a blend of cellulose acetate and a polymer or copolymer of methacrylate ester. The present invention will be explained below. As the cellulose acetate used in the present invention, those having an acetylation degree of 50% to 62% can be used. Further, cellulose acetate having a degree of polymerization of about 80 to 400 can be used. As the methacrylate ester polymer, each polymer of methyl methacrylate, ethyl methacrylate, propyl methacrylate (n or iso), butyl methacrylate (n, iso or tert) and copolymers thereof can be used. be. Examples of the copolymer component used include methyl acrylate, ethyl acrylate, butyl acrylate, but are not limited thereto. The composition of complex acid cellulose and methacrylic acid ester polymer or its copolymer is such that complex acid cellulose is
Although 50% to 90% can be said to be a preferable condition in terms of mechanical strength, it is not limited to this depending on the film forming method. The solvent may be any solvent as long as it dissolves both the cellulose acetate and the methacrylic acid ester (co)polymer. Examples of commonly used ones include methylene chloride, acetone, methyl ethyl ketone, ethyl acetate, N-methylpyrrolidone, and dimethyl sulfoxide. When it is desired to increase the pore diameter of the porous membrane to 0.1 μ or more, a non-solvent is mixed and used as a pore-forming agent. The non-solvent may be any organic liquid that does not dissolve both polymers. Examples include hexane, cyclohexane, cyclohexanol, methanol, ethanol, propanol, butanol, and the like. It is advantageous to add inorganic salts to increase the rate of phase separation and increase the pore size of the membrane. As the inorganic salt, ammonium salt, calcium salt, magnesium salt, etc. can be used. As described above, it is a necessary condition for the film-forming stock solution that the cellulose acetate, the methacrylate ester polymer or its copolymer, the solvent, the non-solvent and the inorganic salt are almost completely dissolved. Before forming a film, it is necessary to remove foreign substances through multiple steps. The polymer concentration is determined based on technical judgment in consideration of the viscosity that facilitates film formation, but is preferably in the range of 5 to 20%. The concentration of non-solvents ranges from 10 to 50%, the salts range from 5 to 10%, and the remainder is the concentration of solvent. If salts are used, it is advantageous to use methanol in concentrations up to 20%. Although these dissolution methods are technically not difficult, first both polymers are completely dissolved in a solvent. In some cases, if the temperature is raised from room temperature to 50°C, it will dissolve in 5 hours. Next, the remaining non-solvent and salt methanol solution are added and stirred for an additional 5 hours to obtain a transparent stock solution. The method for forming a porous membrane from this stock solution is no different from general wet membrane forming, but it differs slightly depending on the form of the porous membrane, such as a flat membrane or a hollow fiber membrane. First, to explain the flat membrane, the above-mentioned stock solution may be cast into water or a water/methanol mixture as a coagulation bath. It is preferable to take care to keep the temperature at 20°C or lower so that the solvent does not easily evaporate. Recently, a method of using a porous membrane as a thin hollow fiber membrane has become popular, so this method will be explained. The polymer stock solution is discharged from the annular spinning hole, and is allowed to fall onto the coagulating liquid surface several cm to several tens of centimeters below the spinning hole.
In this case, the difference from a flat membrane is that the coagulating liquid also flows inside the hollow fiber membrane. As the coagulation bath, water,
Methanol etc. can be used. The temperature of both the stock solution and the coagulation bath is preferably 30°C or lower. Further, it is advantageous to provide a spinning tube below the spinning hole for suppressing solvent evaporation. As mentioned above, the manufacturing method of porous membranes is not particularly different from conventional methods, but by blending cellulose acetate and methacrylic acid ester polymer or copolymer, porous membranes with good material permeability and biocompatibility are created. There is an advantage that a membrane can be obtained. Examples will be described below. Example 1 The stock solution was prepared by adding 120 g and 30 g of cellulose acetate with a degree of axification of 55% and a degree of polymerization of 180 and polymethyl methacrylate with a degree of polymerization of 800, respectively, to 350 g of acetone.
It took 5 hours to dissolve at 50°C. Add 300g of cyclohexanol and add 50g of ammonium chloride.
g and 150 g of methanol were added and stirred. This stock solution was maintained at 20°C, cast onto a glass plate, and solidified in a water:methanol (1:1) coagulation bath. The permeability of this membrane to a 0.2% aqueous solution of bovine serum globulin was measured. As a comparison membrane, a membrane made only of cellulose acetate obtained under similar conditions was used.
【表】
また、上記膜を日本薬局方食塩水に浸漬し、そ
の上に兎血液を滴下して、血液凝固時間を測定し
たが、アセテート多孔性膜より凝固時間の延長が
認められた。
実施例 2
実施例1の原液を用いて、環状紡糸孔より紡出
し、凝固浴は水/メタノール(1:1)を用い、
内側にはポリエチレングライコール(分子量200)
を流出して、下方に5cm落下せしめて、凝固浴に
導き、10m/minで巻取つた。
内径300μ、膜厚85μの中空糸が得られた。
中空糸の性能は下記の通りであつた。[Table] In addition, when the above membrane was immersed in Japanese Pharmacopoeia saline and rabbit blood was dropped onto it to measure the blood coagulation time, it was found that the coagulation time was longer than that of the porous acetate membrane. Example 2 Using the stock solution of Example 1, it was spun from an annular spinning hole, and the coagulation bath was water/methanol (1:1).
Polyethylene glycol (molecular weight 200) inside
It flowed out, was allowed to fall 5 cm downward, was introduced into a coagulation bath, and was wound up at 10 m/min. A hollow fiber with an inner diameter of 300μ and a membrane thickness of 85μ was obtained. The performance of the hollow fiber was as follows.
【表】
実施例 3
原液は醋化度54.5%、重合度190のセルロース
アセテートと重合度900のメタクリル酸メチル−
アクリル酸メチル(90:10)の共重合体を夫々80
g及び20gをアセトン450gに加え、50℃5時間
で溶解する。シクロヘキサン300gを加え、更に
塩化マグネシウム50g及びメタノール150gを加
え撹拌し溶解する。この原液を20℃に保持して、
環状紡糸孔より紡出し、凝固液を内外共に、水/
メタノール(1:1)を用いて中空糸化する。内
径330μ、膜厚75μの中空糸が得られたので、実施
例1のように評価した。[Table] Example 3 The stock solution is cellulose acetate with an axification degree of 54.5% and a polymerization degree of 190, and methyl methacrylate with a polymerization degree of 900.
80 each of copolymers of methyl acrylate (90:10)
Add g and 20 g to 450 g of acetone and dissolve at 50°C for 5 hours. Add 300 g of cyclohexane, then add 50 g of magnesium chloride and 150 g of methanol and dissolve with stirring. Keep this stock solution at 20℃,
Spinning from an annular spinning hole, the coagulating liquid is mixed inside and outside with water/
It is made into a hollow fiber using methanol (1:1). Since a hollow fiber with an inner diameter of 330 μm and a membrane thickness of 75 μm was obtained, it was evaluated as in Example 1.
【表】
実施例 4
醋化度61%、重合度240のセルロースアセテー
トと重合度500のメタクリル酸イソブチル重合体
を夫々40g及び10gをメチレンクロライド250g
に溶解し、更にメタノール75g、塩化カルシウム
25g及びシクロヘキサノール100gを加え撹拌し
て原液を作つた。
この原液を20℃以下に保持し、メタノールの凝
固浴中でガラス基板上に流延して製膜する。この
膜を用いて牛血清γ−グロブリンの0.2%水溶液
の透過性を測定し、次の結果を得た。[Table] Example 4 40 g and 10 g of cellulose acetate with an axification degree of 61% and a polymerization degree of 240 and isobutyl methacrylate polymer with a polymerization degree of 500, respectively, and 250 g of methylene chloride.
75g of methanol, calcium chloride
25 g and 100 g of cyclohexanol were added and stirred to prepare a stock solution. This stock solution is kept at 20°C or lower and cast onto a glass substrate in a methanol coagulation bath to form a film. Using this membrane, the permeability of a 0.2% aqueous solution of bovine serum γ-globulin was measured, and the following results were obtained.
【表】
実施例 5
醋化度55%、重合度180のセルロースアセテー
トと重合度500のメタクリル酸メチル−ビニール
ピロリドン(95:5)共重合体とを夫々135g及
び15gづつアセトン250gに溶解し、更にメタノ
ール75g、硼砂25g及びシクロヘキサノン100g
を加え撹拌して原液を作成した。
この原液を20℃以下に保持し、水/メタノール
(1:1)の凝固溶に流延して製膜し、次の評価
結果を得た。[Table] Example 5 135 g and 15 g of cellulose acetate with an axification degree of 55% and a polymerization degree of 180 and a methyl methacrylate-vinyl pyrrolidone (95:5) copolymer with a polymerization degree of 500 were dissolved in 250 g of acetone, respectively. Additionally, 75g methanol, 25g borax and 100g cyclohexanone.
was added and stirred to prepare a stock solution. This stock solution was maintained at 20° C. or lower and cast into a coagulating solution of water/methanol (1:1) to form a film, and the following evaluation results were obtained.
Claims (1)
体又はその共重合体とのブレンドからなる多孔性
膜。 2 酢化度50〜62%の酢酸セルロースを50〜90重
量%の範囲で含むブレンドであることを特徴とす
る特許請求の範囲第1項記載の多孔性膜。 3 メタクリル酸エステル重合体がメタクリル酸
メチル、メタクリル酸エチル、メタクリル酸プロ
ピル及びメタクリル酸ブチルのいづれかからなる
重合体を含むブレンドであることを特徴とする特
許請求の範囲第1項記載の多孔性膜。[Claims] 1. A porous membrane comprising a blend of cellulose acetate and a methacrylic acid ester polymer or a copolymer thereof. 2. The porous membrane according to claim 1, which is a blend containing 50 to 90% by weight of cellulose acetate with a degree of acetylation of 50 to 62%. 3. The porous membrane according to claim 1, wherein the methacrylate ester polymer is a blend containing a polymer consisting of any one of methyl methacrylate, ethyl methacrylate, propyl methacrylate, and butyl methacrylate. .
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56074133A JPS57194003A (en) | 1981-05-19 | 1981-05-19 | Porous membrane |
| DE8282302529T DE3276853D1 (en) | 1981-05-19 | 1982-05-18 | Porous membrane |
| EP82302529A EP0066408B1 (en) | 1981-05-19 | 1982-05-18 | Porous membrane |
| US06/379,698 US4459210A (en) | 1981-05-19 | 1982-05-19 | Porous membrane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56074133A JPS57194003A (en) | 1981-05-19 | 1981-05-19 | Porous membrane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57194003A JPS57194003A (en) | 1982-11-29 |
| JPS6352923B2 true JPS6352923B2 (en) | 1988-10-20 |
Family
ID=13538380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56074133A Granted JPS57194003A (en) | 1981-05-19 | 1981-05-19 | Porous membrane |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS57194003A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4877421A (en) * | 1987-11-02 | 1989-10-31 | Union Carbide Corporation | Treatment of permeable membranes |
-
1981
- 1981-05-19 JP JP56074133A patent/JPS57194003A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57194003A (en) | 1982-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4439322A (en) | Polymethyl methacrylate membrane | |
| Lin et al. | Nonsolvent-induced gelation and its effect on membrane morphology | |
| US4075108A (en) | Polycarbonate membranes and production thereof | |
| KR100284911B1 (en) | Hydrophilic materials and semipermeable membranes using the same | |
| EP0066408B1 (en) | Porous membrane | |
| US4160791A (en) | Polycarbonate membranes and production thereof | |
| JPS5891732A (en) | Porous polyvinylidene fluoride resin membrane and preparation thereof | |
| JPH0278425A (en) | Hydrophilic and dryable semipermeable membrane based on polyvinylidene fluoride | |
| Chen et al. | Effect of nonsolvents on the mechanism of wet-casting membrane formation from EVAL copolymers | |
| JPS6352923B2 (en) | ||
| US4678581A (en) | Polymethyl methacrylate hollow fiber type ultrafiltration membrane and process for preparation of the same | |
| USRE30856E (en) | Polycarbonate membranes and production thereof | |
| JPH0536065B2 (en) | ||
| JPS6312173B2 (en) | ||
| JPS5891731A (en) | Asymmetrical porous membrane of polyvinyl fluoride and its production | |
| JP4659166B2 (en) | Film-forming stock solution and method for producing ethylene-vinyl alcohol polymer film | |
| JPH0359733B2 (en) | ||
| JPH09225274A (en) | Membrane forming solution and method for producing ethylene-vinyl alcohol copolymer membrane | |
| JPH0360530B2 (en) | ||
| RU2192301C1 (en) | Method of producing membrane tubular filtering members | |
| JPS6260122B2 (en) | ||
| JPS6353849B2 (en) | ||
| JPH04108523A (en) | Manufacture of cyclodextrin membrane | |
| JPS59139902A (en) | Preparation of permselective membrane | |
| JPS608012B2 (en) | Method for manufacturing amphoteric ion exchange composite membrane |